(48) developed a model based on deep learning and pre-treatment CT for a multicenter prognostic study to predict the survival benefits of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) and immune checkpoint inhibitors (ICI) in stage IV non-small cell lung cancer (NSCLC) patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.